Circulating chemokine (C-X-C Motif) receptor 5+CD4+ T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection

Hepatology

Volumn 58, Issue 4, 2013, Pages 1277-1286

  Li, Yongyin ^a   Ma, Shiwu ^a,b   Tang, Libo ^a   Li, Yun ^a   Wang, Wei ^c   Huang, Xuan ^a   Lai, Qintao ^a   Zhang, Mingxia ^a   Sun, Jian ^a   Li, Chris Kafai ^d   Abbott, William G H ^e   Naoumov, Nikolai V ^f   Zhang, Yu ^c   Hou, Jinlin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b KUNMING GENERAL HOSPITAL   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR5; FC RECEPTOR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; RECOMBINANT CYTOKINE; TELBIVUDINE; VIRUS DNA;

ANTIBODY PRODUCTION; ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; COCULTURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CXCR5+ CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; HYPERSPLENISM; IN VITRO STUDY; LIVER CIRRHOSIS; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEROCONVERSION; SPLEEN; SPLENECTOMY; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKINS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, CXCR5; RECOMBINANT PROTEINS; THYMIDINE; YOUNG ADULT;

EID: 84884979909     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26489     Document Type: Article

References (23)

1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
2. Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010;51:415-421.
3. European AFTS. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
4. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol 2005;23:487-513.
5. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-663.
6. Moser B, Schaerli P, Loetscher P. CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses. Trends Immunol 2002;23:250-254.
7. Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, et al. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol 2011;186:5556-5568.
8. Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010;62:234-244.
9. Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011;34:108-121.
10. Linterman MA, Vinuesa CG. Signals that influence T follicular helper cell differentiation and function. Semin Immunopathol 2010;32:183-196.
11. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000;192:1553-1562.
12. Ma SW, Huang X, Li YY, Tang LB, Sun XF, Jiang XT, et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol 2012;56:775-781.
13. Hu X, Ma S, Huang X, Jiang X, Zhu X, Gao H, et al. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat 2011;18:458-467.
14. Liang M, Ma S, Hu X, Zhou B, Zhang J, Chen J, et al. Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy. Virol J 2011;8:69.
15. Ward SM, Phalora P, Bradshaw D, Leyendeckers H, Klenerman P. Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus. J Infect Dis 2008;198:813-817.
16. Tuaillon E, Tabaa YA, Petitjean G, Huguet MF, Pajeaux G, Fondere JM, et al. Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay. J Immunol Methods 2006;315:144-152.
17. Mathew A, West K, Kalayanarooj S, Gibbons RV, Srikiatkhachorn A, Green S, et al. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis 2011;204:1514-1522.
18. Kessel A, Haj T, Peri R, Snir A, Melamed D, Sabo E, Toubi E. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev 2012;11:670-677.
19. Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005;42:1028-1036.
20. Publicover J, Goodsell A, Nishimura S, Vilarinho S, Wang ZE, Avanesyan L, et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011;121:1154-1162.
21. Hu CR, Chen CB, Tan XB, Shi TD. Effects of IL-21 on B lymphocytes proliferation and HBeAb production in chronic hepatitis B patients. Immunol J 2011;27:126-138.
22. Konforte D, Simard N, Paige CJ. IL-21: an executor of B cell fate. J Immunol 2009;182:1781-1787.
23. Chen M, Sallberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005;79:3016-3027.